A new drug combo called amivantamab-chemotherapy improved survival in patients with advanced lung cancer that has an EGFR exon 20 insertion mutation.
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Amivantamab-chemotherapy demonstrates longest overall survival reported for lung cancer with EGFR mutation
Phase 3 PAPILLON Study phase
Non-Small Cell Lung Cancer Cancer type
EGFR Exon 20 Insertion Mutation targeted
Previously Untreated Advanced Patients treated